Short summary: SURPASS-CVOT is the key cardiovascular outcomes trial for tirzepatide in people with type 2 diabetes and established atherosclerotic cardiovascular disease. The trial found that tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events. It did not prove superiority for the primary heart-outcome endpoint.
Key takeaways
- Tirzepatide is a GIP and GLP-1 receptor agonist used for type 2 diabetes under the Mounjaro brand.
- SURPASS-CVOT compared tirzepatide with dulaglutide, not placebo.
- The primary cardiovascular outcome showed noninferiority, meaning tirzepatide was not worse than dulaglutide by the trial’s prespecified margin.
- Weight, A1C, blood pressure, and some risk markers may improve, but those changes are not the same as proving fewer heart attacks or strokes for every patient.
Why SURPASS-CVOT matters
Many diabetes medicines lower glucose, but cardiovascular outcomes trials ask a different question: what happens to heart attack, stroke, cardiovascular death, or related events in people at high heart risk?
This matters because people with type 2 diabetes often have overlapping heart risks, including high blood pressure, cholesterol problems, kidney disease, smoking history, and prior cardiovascular disease.
What the trial studied
SURPASS-CVOT enrolled adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It compared tirzepatide with dulaglutide. Dulaglutide was an active comparator with established cardiovascular benefit, so this was a demanding comparison.
The primary endpoint was a standard major adverse cardiovascular event outcome, commonly called MACE. It included cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
What it showed
The main result was noninferiority of tirzepatide compared with dulaglutide for the primary cardiovascular endpoint. In plain language, tirzepatide did not show unacceptable extra cardiovascular risk compared with dulaglutide in this trial population.
That is important, but it should not be inflated. Noninferiority is not the same as proving tirzepatide is better for heart outcomes. Trial details also apply most directly to people like those enrolled in the study.
Where SURMOUNT fits
SURMOUNT trials studied tirzepatide for obesity and weight management outcomes. These studies showed substantial weight loss in trial settings and have reported improvements in some cardiometabolic risk markers. Weight loss and blood pressure changes can be meaningful, but they do not replace a dedicated cardiovascular outcomes result.
What patients should not take from this
This trial does not mean tirzepatide is the right medicine for everyone. It does not remove the need for blood pressure treatment, cholesterol treatment, smoking cessation, kidney care, or individualized diabetes goals. It also does not mean someone should switch medicines based on headlines.
For related medication context, read GLP-1 Medicines and Kidney Protection and Amycretin: What to Know.
Practical takeaway
SURPASS-CVOT is reassuring cardiovascular evidence for tirzepatide compared with dulaglutide in a high-risk type 2 diabetes trial population, but it is not a reason to change medication without a clinician. Heart-risk care still depends on the full plan: glucose, blood pressure, LDL cholesterol, kidney health, smoking status, weight, side effects, access, and preferences.
Sources
- NEJM: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
- American College of Cardiology: SURPASS-CVOT Journal Scan
- DailyMed: Mounjaro Tirzepatide Prescribing Information
- NEJM: Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1
- PubMed: Tirzepatide and Blood Pressure Reduction, SURMOUNT-1 Analysis
Editorial review note: reviewed for medical accuracy, source consistency, trial-name accuracy, medication-label caveats, cardiovascular safety framing, and plain-language readability before publication.